HBM contact: Dr Emil Bujak
BioShin is a development and commercialization company
focused on advancing therapies for which there are currently no adequate
treatment options. Our current clinical programs span a range of innovative, late-stage product candidates targeting neurological diseases. Bioshin is
the Asia-Pacific subsidiary of Biohaven Pharmaceuticals.